Is Spotify a Millionaire-Maker Stock?
Spotify (NYSE:SPOT) may seem like an expensive proposition trading closer…
Buy
59
AUPH Quote, Financials, Valuation and Earnings
Last price:
$8.00
Seasonality move
:
-3.28%
Day range:
$7.93 - $8.21
52-week range:
$4.99 - $10.67
Dividend yield:
0%
P/E ratio:
160.00x
P/S ratio:
4.96x
P/B ratio:
2.90x
Volume:
1.5M
Avg. volume:
1.2M
1-year change:
54.74%
Market cap:
$1.1B
Revenue:
$235.1M
EPS (TTM):
$0.05
Analysts' Opinion
-
Consensus RatingAurinia Pharmaceuticals has received a consensus rating of Buy. The company's average rating is a Buy based on 3 Buy ratings, 1 Hold rating, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $9.83, Aurinia Pharmaceuticals has an estimated upside of 22.92% from its current price of $8.00.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $8.00 representing 100% downside risk from its current price of $8.00.
Fair Value
-
According to the consensus of 4 analysts, Aurinia Pharmaceuticals has 22.92% upside to fair value with a price target of $9.83 per share.
AUPH vs. S&P 500
-
Over the past 5 trading days, Aurinia Pharmaceuticals has underperformed the S&P 500 by -2.17% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Aurinia Pharmaceuticals does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Aurinia Pharmaceuticals has grown year-over-year revenues for 5 quarters straight. In the most recent quarter Aurinia Pharmaceuticals reported revenues of $59.9M.
Earnings Growth
-
Aurinia Pharmaceuticals earnings have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Aurinia Pharmaceuticals reported earnings per share of $0.01.
Enterprise value:
734.7M
EV / Invested capital:
--
Price / LTM sales:
4.96x
EV / EBIT:
59.81x
EV / Revenue:
3.12x
PEG ratio (5yr expected):
--
EV / Free cash flow:
16.66x
Price / Operating cash flow:
26.46x
Enterprise value / EBITDA:
23.16x
Gross Profit (TTM):
$206.9M
Return On Assets:
1.07%
Net Income Margin (TTM):
2.45%
Return On Equity:
1.54%
Return On Invested Capital:
1.54%
Operating Margin:
22.85%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Income Statement | ||||||
| Revenue | $134M | $175.5M | $235.1M | $45.1M | $59.9M | |
| Gross Profit | $128.4M | $161.4M | $206.9M | $39.7M | $54.3M | |
| Operating Income | -$111.5M | -$91.7M | $18.4M | -$29.7M | $13.7M | |
| EBITDA | -$103.9M | -$57.2M | $31.7M | -$20.2M | $7.2M | |
| Diluted EPS | -$0.76 | -$0.53 | $0.05 | -$0.18 | $0.01 | |
| Period Ending | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $419.4M | $513.3M | $442.5M | $424.8M | $446.6M | |
| Total Assets | $463.7M | $543.4M | $470.9M | $548.1M | $550.6M | |
| Current Liabilities | $32M | $40.6M | $46.1M | $77.2M | $97.8M | |
| Total Liabilities | $55.9M | $64.3M | $65.4M | $170.1M | $173.2M | |
| Total Equity | $407.8M | $479.1M | $405.4M | $378M | $377.5M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$79.5M | -$33.5M | $44.4M | $14.3M | $30.1M | |
| Cash From Investing | -$60.6M | -$6.7M | $39.3M | -$6.3M | $39.2M | |
| Cash From Financing | $2.4M | -$5.1M | -$49.1M | -$5.6M | -$23M | |
| Free Cash Flow | -$79.8M | -$34.2M | $44.1M | $14.3M | $30.1M | |
AUPH
Sector
Market Cap
$1.1B
$33.9M
Price % of 52-Week High
74.98%
44.2%
Dividend Yield
0%
0%
Shareholder Yield
3.18%
-0.74%
1-Year Price Total Return
54.74%
-40.43%
Beta (5-Year)
1.160
0.660
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$8.16
200-day SMA
Buy
Level
$7.69
Bollinger Bands (100)
Sell
Level
7.71 - 8.65
Chaikin Money Flow
Sell
Level
-175.5M
20-day SMA
Buy
Level
$7.98
Relative Strength Index (RSI14)
Sell
Level
48.76
ADX Line
Sell
Level
15.75
Williams %R
Neutral
Level
-60.3175
50-day SMA
Sell
Level
$8.07
MACD (12, 26)
Buy
Level
0.04
25-day Aroon Oscillator
Buy
Level
64
On Balance Volume
Neutral
Level
361.9M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (3.2631)
Buy
CA Score
(Annual)
Level (0.6645)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (10)
Buy
Ohlson Score
Level (-8.9988)
Buy
Piotroski F Score
(Annual)
Level (6)
Buy
Quality Ratio Score
Level (6)
Buy
Fundamental Score
Level (6)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.
Stock Forecast FAQ
In the current month, AUPH has received 3 Buy ratings 1 Hold ratings, and 0 Sell ratings. The AUPH average analyst price target in the past 3 months is $9.83.
-
Where Will Aurinia Pharmaceuticals Stock Be In 1 Year?
According to analysts, the consensus estimate is that Aurinia Pharmaceuticals share price will rise to $9.83 per share over the next 12 months.
-
What Do Analysts Say About Aurinia Pharmaceuticals?
Analysts are divided on their view about Aurinia Pharmaceuticals share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Aurinia Pharmaceuticals is a Sell and believe this share price will drop from its current level to $8.00.
-
What Is Aurinia Pharmaceuticals's Price Target?
The price target for Aurinia Pharmaceuticals over the next 1-year time period is forecast to be $9.83 according to 4 Wall Street analysts, 3 of them rate the stock a Buy, 0 rate the stock a Sell, and 1 analyst rates the stock a Hold.
-
Is AUPH A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Aurinia Pharmaceuticals is a Buy. 3 of 4 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of AUPH?
You can purchase shares of Aurinia Pharmaceuticals via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Aurinia Pharmaceuticals shares.
-
What Is The Aurinia Pharmaceuticals Share Price Today?
Aurinia Pharmaceuticals was last trading at $8.00 per share. This represents the most recent stock quote for Aurinia Pharmaceuticals. Yesterday, Aurinia Pharmaceuticals closed at $8.00 per share.
-
How To Buy Aurinia Pharmaceuticals Stock Online?
In order to purchase Aurinia Pharmaceuticals stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
What Is a Millionaire-Maker Stock?
From time to time, investors will run across the term…
5 Investors to Follow Other Than Warren Buffett
There is no doubt that Warren Buffett is one of…
Stock Ideas
Buy
68
Is MSFT Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 37x
Sell
39
Is AAPL Stock a Buy?
Market Cap: $3T
P/E Ratio: 33x
Buy
61
Is NVDA Stock a Buy?
Market Cap: $2.8T
P/E Ratio: 40x
Alerts
Sell
50
QDEL alert for May 10
QuidelOrtho [QDEL] is down 0.22% over the past day.
Buy
97
NGVC alert for May 10
Natural Grocers by Vitamin Cottage [NGVC] is up 30.26% over the past day.
Sell
38
ONTO alert for May 10
Onto Innovation [ONTO] is down 30.17% over the past day.
